COVID-19 leads to Hyperactivity in blood clotting cells leading to increased risk of severe diseases
even post recovery.
COVID-19 alters the functioning of platelets, leading them to aggregate faster,
which explains why doctors are seeing increased numbers of blood clots in COVID patients.
Researchers studied 41 COVID-19 patients
& compared their blood samples with those of healthy individuals.
Differential gene analysis indicated that
SAR-CoV-2 virus trigger some genetic changes in the platelets,
altering how platelets interacts with immune system.
Interestingly, no evidence of the virus was detected in the majority of platelets,
suggesting that it could be promoting the genetic changes within these cells indirectly.
Inflammation caused by COVID-19 could affect megakaryocytes, the cells that produce platelets. As a
result, critical genetic alterations are passed down from megakaryocytes to the platelets, which, in
turn, make them hyperactive.
This increases the risk of increased risk of blood clotting, which can lead to cardiovascular problems
and organ failure in some patients, particularly among those with underlying medical problems such
as diabetes, obesity, or high blood pressure.
